Esreboxetine
Esreboxetine is a selective norepinephrine [reuptake inhibitor] which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued. It is the --enantiomer of reboxetine and is even more selective as a norepinephrine reuptake inhibitor in comparison.
However, recently it has been found that esreboxetine could be effective in fibromyalgia patients.